Atara Biotherapeutics Inc
$
31.86
-0.72 (-2.21%)
| Volume: | 401,240 | Avg Vol (1m): | 432,983 |
| Market Cap $: | 1.47 Bil | Enterprise Value $: | 1.16 Bil |
| P/E (TTM): | 0.00 | P/B: | 4.31 |
| Earnings Power Value | 3.72 |
| Net Current Asset Value | 5.86 |
| Tangible Book | 7.4 |
| Projected FCF | 0 |
| Median P/S Value | 0 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
YTD (-%)
Add to portfolio
Email alerts
Stock PDF
RSS
Website
Filings
Download Excel
Batch Download
Manual of Stocks™ Web
Manual of Stocks™
Manual of Stocks™ Web
Manual of Stocks™
Financial Strength : 8/10
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | No Debt | N/A | |
| Interest Coverage | No Debt | N/A | |
| Piotroski F-Score | 3 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 13.69 |
DISTRESS
GREY
SAFE
| |
| WACC vs ROIC % |
ROIC -807.15%
WACC 22.97%
| ||
Profitability & Growth : 3/10
| Current | vs industry | vs history | |
|---|---|---|---|
| ROE % | -63.68 | ||
| ROA % | -57.15 | ||
| ROC (Joel Greenblatt) % | -388.38 | ||
| 3-Year Total EBITDA Growth Rate | -58.70 | N/A | |
| 3-Year EPS w/o NRI Growth Rate | -33.00 | N/A |
» ATRA's 30-Y Financials
Financials (Next Earnings Date: 2019-05-08)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:ATRA
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 325412   SIC : 2836 |
| Compare | TSE:4565 NAS:ENTA NAS:IOVA NAS:ICPT TSE:4592 SZSE:002030 OSTO:VITR NAS:RGEN NAS:PRTA NAS:IMGN XKRX:005250 XSWX:SFZN NAS:MDGL NAS:INVA NAS:XNCR NAS:TBPH NAS:ARNA NAS:INSM SZSE:002275 BOM:539268 |
| Traded in other countries | AT2.Germany |
| Address | 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080 |
| Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening diseases. The company achieves this through two groups of product candidates, such as allogenic or third-party derived antigen-specific T-cells and molecularly targeted biologics. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 4.31 | ||
| EV-to-EBIT | -4.90 | ||
| EV-to-EBITDA | -4.98 | ||
| Current Ratio | 8.04 | ||
| Quick Ratio | 8.04 |
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -15.50 |
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 4.31 | ||
| Earnings Yield (Joel Greenblatt) % | -20.41 |
More Statistics
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 3 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | N |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | N |